Beyond COVID: How mRNA Platforms Are Rebuilding Around Cancer and Rare Disease in 2026

Jul 28
2 min read

The mRNA platform is proving its post-pandemic staying power. Mordor Intelligence values the global mRNA vaccines and therapeutics market at $74.43 billion in 2026, up from $63.88 billion in 2025, and projects it will reach $159.59 billion by 2031, a 16.5% CAGR. The more important shift isn't the growth rate, it's what the platform is being used for: mRNA is transitioning from an emergency-centric COVID-19 model into a broader therapeutic platform spanning oncology, rare diseases, and autoimmune disorders.

Cancer Is Now a Quarter of the Pipeline

mRNA cancer vaccines and therapeutics now represent roughly 25% of the broader mRNA market, according to Research and Markets, with five mRNA vaccine developers having already reached regulatory approval across different indications. That's a meaningful validation point: this is no longer a platform proving out one use case, it's demonstrating repeatable success translating from infectious disease into fundamentally different therapeutic areas.

Where the Investment Is Flowing

The Coalition for Epidemic Preparedness Innovations committed up to $54.3 million in December 2025 to advance Moderna's mRNA-1018 pandemic influenza candidate into Phase III trials
Self-amplifying RNA (saRNA) is projected to be the fastest-growing mRNA modality through 2034, offering manufacturing advantages over conventional mRNA
In-house manufacturing still dominates with roughly 64% market share, as major pharma companies prioritize proprietary control over mRNA intellectual property
Outsourced CDMO manufacturing is expanding quickly, giving smaller biotech firms access to validated mRNA production without capital-intensive infrastructure

AI Is Reaching Into RNA Design Itself

AI integration is emerging as its own growth driver within the RNA therapeutics category, with AI-driven models increasingly used to interpret concealed signaling patterns in cancer biology and guide antigen selection. Combined with dedicated regulatory pathways for faster review and rising investment in scalable manufacturing, the platform is positioned for a materially broader second act than its pandemic-era origin story.

What It Means for the Market

The mRNA platform's expansion into oncology and rare disease is the clearest evidence yet that its post-pandemic value proposition holds up beyond infectious disease. As saRNA technology matures and CDMO capacity broadens access for smaller biotech players, expect competitive dynamics to shift from who can manufacture at scale toward who can pair AI-guided antigen design with the fastest regulatory pathway to market.

Related Reports

Explore our latest coverage of vaccines and biotech-adjacent markets: